AJW.F · AnGes, Inc

-

Please sign in to comment on AJW.F

1 Comment

Admin

4 years ago

AnGes, Inc is currently in a long term downtrend where the price is trading 35.3% below its 200 day moving average.

From a valuation standpoint, the stock is 161.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 3439.1.

AnGes, Inc's total revenue rose by 318.2% to $12M since the same quarter in the previous year.

Its net income has dropped by 5.6% to $-1B since the same quarter in the previous year.

Finally, its free cash flow fell by 0.0% to $-1B since the same quarter in the previous year.

Based on the above factors, AnGes, Inc gets an overall score of 1/5.

Sector	Healthcare
Industry	Biotechnology
ISIN	JP3127700007
Exchange	F
CurrencyCode	EUR

Beta	1.5
Market Cap	141M
PE Ratio	None
Target Price	None
Dividend Yield	None

ABOUT

AnGes, Inc

AnGes, Inc. engages in the research and development of gene-based medical products. It develops HGF gene therapy product for the treatment of ischemic diseases; NF-"B Decoy Oligo DNA for chronic discogenic lumber back pain; and DNA vaccines for the treatment of hypertension and cervical intraepithelial neoplasia, as well as intranasal formulation of the COVID-19 vaccine. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.

AJW.F · AnGes, Inc

-

AnGes, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest AnGes, Inc using a moving average strategy